A citation-based method for searching scientific literature

Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
Times Cited: 363



Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Circulation 2019
Times Cited: 256




List of shared articles



Times cited



GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Juris J Meier. Mol Metab 2021
34


Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Hirotaka Miyashita, Takahisa Mikami, Hiroki Ueyama, Tomohiro Fujisaki, Yusuke Saigusa, Takahiro Yamaji,[...]. Cardiovasc Diabetol 2021
7

Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease.
Adam J Nelson, Maddalena Ardissino, Kevin Haynes, Sonali Shambhu, Zubin J Eapen, Darren K McGuire, Anthony Carnicelli, Renato D Lopes, Jennifer B Green, Emily C O'Brien,[...]. J Am Heart Assoc 2021
7

Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
Marta Baviera, Stefano Genovese, Vito Lepore, Pierluca Colacioppo, Fabio Robusto, Mauro Tettamanti, Antonio D'Ettorre, Fausto Avanzini, Ida Fortino, Antonio Nicolucci,[...]. Diabetes Obes Metab 2021
0

Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.
Muhammad Imtiaz Ahmad, Michael D Shapiro. Curr Atheroscler Rep 2021
1

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Moa Lugner, Naveed Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzén, Ann-Marie Svensson, Björn Eliasson. Cardiovasc Diabetol 2021
3

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J L Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl. Cardiovasc Diabetol 2021
1

Can the in-hospital mortality gap between STEMI patients with and without diabetes mellitus be reduced? The cardio-renal hypothesis.
Nicola Cosentino, Alice Bonomi, Jeness Campodonico, Fabrizio Veglia, Gaetano M De Ferrari, Stefano Genovese, Giancarlo Marenzi. Nutr Metab Cardiovasc Dis 2021
0


Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Peyman Nowrouzi-Sohrabi, Negin Soroush, Reza Tabrizi, Mojtaba Shabani-Borujeni, Shahla Rezaei, Fatemeh Jafari, Mahnaz Hosseini-Bensenjan, Bruno H Stricker, Mandy van Hoek, Fariba Ahmadizar. Front Pharmacol 2021
1

Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies.
Omar S Alkhezi, Haifa A Alsuhaibani, Amal A Alhadyab, Mashael E Alfaifi, Basmah Alomrani, Ali Aldossary, Osamah M Alfayez. Prim Care Diabetes 2021
0

Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Jack Wei Chieh Tan, David Sim, Junya Ako, Wael Almahmeed, Mark E Cooper, Jamshed J Dalal, Chaicharn Deerochanawong, David Wei Chun Huang, Sofian Johar, Upendra Kaul,[...]. Eur Cardiol 2021
0